

The Royal Australasian College of Physicians

Clinical Immunology and Allergy Advanced Training Curriculum

Adult Medicine Division Paediatrics & Child Health Division







The Royal Australasian College of Physicians

Physician Readiness for Expert Practice (PREP) Training Program

Clinical Immunology and Allergy Advanced Training Curriculum

TO BE USED IN CONJUNCTION WITH:

Basic Training Curriculum - Adult Internal Medicine Basic Training Curriculum - Paediatrics & Child Health Professional Qualities Curriculum

ACKNOWLEDGEMENTS

The Royal Australasian College of Physicians (RACP) Fellows, trainees, and staff have contributed to the development of this document.

The College specifically thanks those Fellows and trainees who have generously contributed to the development of this curriculum, through critical comments drawn from their knowledge, experience and the donation of their time and professional expertise.

The following Fellows and trainees, in particular, deserve specific mention for their contribution:

- Dr Stephen Adelstein, FRACP, FRCPA
- A/Prof Matthew Cook, FRACP, FRCPA
- A/Prof David Fulcher, FRACP FRCPA
- Prof Bradley Frankum, FRACP
- Dr Robert Heddle, FRACP, FRCPA
- Dr Tiffany Hughes, FRACP, FRCPA
- Dr Fredrick Lee
- Prof Dominic Mallon, FRACP, FRCPA
- Dr Sam Mehr, FRACP
- Dr Karen Morwood, FRACP
- A/Prof Mimi Tang, FRACP, FRCPA
- Dr Melanie Wong, FRACP, FRCPA
- Dr Richard Wong, FRACP, FRCPA

The RACP gratefully acknowledges the contribution of the Australasian Society of Clinical Immunology and Allergy to the development of this curriculum.

The process was managed by the Curriculum Development Unit within the College's Education Deanery, who designed this document, drafted content material, organised and facilitated writing workshops, developed resource materials, and formatted the final document.

CONTACT DETAILS

THE ROYAL AUSTRALASIAN COLLEGE OF PHYSICIANS

AUSTRALIA

145 Macquarie Street Sydney NSW 2000 Australia

Tel: (+61) (2) 9256 5444 Fax: (+61) (2) 9252 3310

Email: racp@racp.edu.au Website: www.racp.edu.au

AOTEAROA NEW ZEALAND

Level 10 3 Hunter Street Wellington 6011 New Zealand

Tel: (+64) (4) 472 6713 Fax: (+64) (4) 472 6718

Email: racp@racp.org.nz Website: www.racp.edu.au


COPYRIGHT

1st edition 2010 (revised 2013).

Please note: No Domains, Themes or Learning Objectives have been updated for this edition; design changes ONLY.

Copyright © 2013. The Royal Australasian College of Physicians (RACP). All rights reserved. Published December 2013.

This work is copyright. Apart from any fair use, for the purposes of study or research, it may not be reproduced in whole or in part, by any means electronic or mechanical, without written permission from The Royal Australasian College of Physicians



RACP FELLOWSHIP TRAINING PATHWAYS AND THE CONTINUUM OF LEARNING

Trainees must complete Basic Training in Paediatrics & Child Health to enter this program. Ρ

Trainees must complete Basic Training in Adult Medicine to enter this program. Trainees who have entered Advanced Training in Palliative Medicine via a RACP Basic Training Program will be awarded FRACP upon completion and may subsequently be awarded FAChPM. Trainees who have NOT entered Advanced Training in Palliative Medicine via a RACP Basic Training Program will only be awarded FAChPM upon completion.

The Child & Adolescent Psychiatry Joint Training Program with the Royal Australian and New Zealand College of Psychiatrists (RANZCP) is currently under review by the RACP and RANZCP and closed to new entrants at present.

Alternative entry requirements exist for these training programs; please see the corresponding PREP Program Requirements Handbook for further information.

NB1: This diagram only depicts training programs that lead to Fellowship. Please see the RACP website for additional RACP training programs. NB2: For further information on any of the above listed training programs, please see the corresponding PREP Program Requirements Handbook.

OVERVIEW OF THE SPECIALTY

Clinical immunology and allergy physicians care for patients with a diverse range of disorders of the immune system. These fall into three major categories:

- allergic disorders
- immune deficiency disorders
- autoimmune diseases

The casemix for each practitioner varies according to whether the practitioner sees adult patients or children, whether the practitioner works in the community or in tertiary teaching hospitals, and according to the traditional referral patterns within their geographical location.

The diversity of clinical immunology and allergy means that it is a horizontally rather than vertically defined discipline. As such, many patients are referred with ill defined disorders for which immunological conditions such as immunodeficiency, autoimmunity and allergy form but part of the differential diagnosis. Whilst it is not appropriate to list many of these presentations in the specific curriculum, trainees will encounter and be expected to learn to deal with such patients with skill and compassion.

Clinical immunology and allergy

The location and orientation of practices are as diverse as the specialty. Employment varies from full-time hospital/ university practice through to full-time private practice. Allergy and primary immunodeficiency are major components of many practices; participation in immunopathology varies greatly as does involvement in systemic and organ specific autoimmunity; and acquired immunodeficiency with these latter fields overlapping enormously with other specialties.

Paediatric clinical immunology and allergy

Paediatric clinical immunology and allergy physicians within Australia are smaller in number than their colleagues in adult medicine. The majority of practitioners in this area have trained under the Specialist Adivsory Committee (SAC) in general paediatrics before or while training in immunology and allergy. Relatively few have trained under the Joint Specialist Advisory Committee (JSAC), and fewer still have trained in immunopathology. Employment is again diverse. Allergy is a major component of most practices, involvement in primary immunodeficiency varies. These practitioners will see relatively few children with chronic systemic autoimmune or inflammatory disorders, or children with HIV, as these are rare conditions in childhood in Australia and New Zealand and referral patterns overlap with those of paediatric rheumatologists and infectious diseases physicians. This group will also include practitioners who have a specific interest in vaccine immunology.

All consultants within the specialty will require a working knowledge of the natural history of immune disorders across the life span. Many practitioners, especially in areas with severe shortages of consultants, see children and adults. There is an obligation upon all practitioners to recognise and practise within their limits of competence.

More clinical immunology and allergy physicians are required to care for the rising numbers of patients with immunological disorders.

Trainees who choose this diverse and challenging subspecialty are guaranteed to be busy.

There has been a substantial rise in prevalence of disorders of immune regulation (most notably allergic, inflammatory and autoimmune disorders) and of acquired immunodeficiency diseases in the last 30 years of the 20th century. The impact of this rise is already being felt in paediatrics, and will inevitably flow through to adult practice. This will require our subspecialty to adapt to the increasing number of patients that require specialist care.

Although accurate manpower statistics for the subspecialty are not available at the present time, rising waiting times for new appointments for immunologists and allergists suggest a significant shortage of practitioners in this subspecialty.

CURRICULUM OVERVIEW

Clinical Immunology and Allergy - Advanced Training Curriculum

This curriculum is to be used in conjunction with the Professional Qualities Curriculum (PQC) which outlines the broad concepts, related learning objectives; associated theoretical knowledge, clinical skills, attitudes and behaviours required and commonly used by clinical immunology and allergy physicians within Australia and New Zealand.

The purpose of Advanced Training is for trainees to build on the cognitive and practical skills acquired during Basic Training. At the completion of the Clinical Immunology and Allergy Advanced Training Program, trainees should be competent to provide at consultant level, unsupervised comprehensive medical care in clinical immunology and allergy.

Attaining competency in all aspects of this curriculum is expected to take three years of training. It is expected that all teaching, learning and assessment associated with the Clinical Immunology and Allergy Curriculum will be undertaken within the context of the physician's everyday clinical practice and will accommodate discipline-specific contexts and practices. As such it will need to be implemented within the reality of current workplace and workforce issues and the needs of health service provision.

There may be learning objectives that overlap with or could easily relate to other domains. However, to avoid repetition, these learning objectives have been assigned to only one area. In practice, it is anticipated that within the teaching/ learning environment, the progression of each objective would be explored.

Note: The curricula should always be read in conjunction with the relevant College Training Handbook available on the College website.

Professional Qualities Curriculum

The PQC outlines the range of concepts and specific learning objectives required by, and used by, all physicians, regardless of their specialty or area of expertise. It spans both the Basic and Advanced Training Programs and is also used as a key component of the CPD program.

Together with the various Basic and Advanced Training curricula, the PQC integrates and fully encompasses the diagnostic, clinical, and educative-based aspects of the physician's/paediatrician's daily practice.

Each of the concepts and objectives within the PQC will be taught, learnt, and assessed within the context of everyday clinical practice. Thus, it is important, that they be aligned with, and fully integrated into, the learning objectives within this curriculum.

EXPECTED OUTCOMES AT THE COMPLETION OF TRAINING

Graduates from this training program will be equipped to function effectively within current and emerging professional, medical, and societal contexts. At the completion of the Advanced Training Program in Clinical Immunology and Allergy, as defined by this curriculum, it is expected that a new Fellow will have developed the clinical skills and have acquired the theoretical knowledge for competent clinical immunology and allergy practice.

The following generic skills will be developed by the trainee and applied to the assessment and care of patients with suspected immunological disorders:

- take a relevant history and competently perform a clinical examination
- formulate a differential diagnosis
- request appropriate diagnostic tests
- explain the details of diagnosis, natural history and outcome of immunological disorders and the required therapeutic measures to clinical colleagues, patients, and their carers
- develop management plans, including education about triggering or exacerbating factors, specific treatment, disease prevention and longer term management
- communicate effectively with patients, their families and working colleagues
- work effectively within a multidisciplinary team to plan the optimal long-term management of patients
- evaluate and use available evidence to solve difficult diagnostic and management problems
- recognise the limitations of their own expertise and refer patients appropriately.

Related generic skills include the ability of the trainee to:

- access available disease registries and be able to use them
- maintain involvement in a CPD program
- advise patients of patient support organisations and how to access them.

In addition, this training program will ensure that trainees are:

- knowledgeable and competent in the diagnosis and management of common immunological and allergic diseases
- skilled in quality assurance activities, such as clinical audit
- advocates for, and responsible managers of, the available health care resources
- continuing to learn about new developments in this rapidly expanding field
- able to impart their knowledge to all levels of society
- honest, compassionate and display the highest standards of personal and interpersonal professional behaviours.

Teaching and learning methods

The teaching and learning methods within this document cater for the range of adult learning styles, situations, and processes likely to be experienced within the majority of professional environments. A range of core teaching and learning strategies is presented in the following list.

- 1. lectures
- 2. tutorials and seminars
- 3. demonstrations/observation
- 4. task performance/practice/observation
- 5. assignments/projects
- 6. research, including audits
- 7. conferences/workshops
- 8. journal clubs
- 9. clinics/tailored clinical experiences
- 10. ward rounds
- 11. grand rounds
- 12. committee/multidisciplinary team meetings
- 13. mentoring
- 14. coaching
- 15. simulations computer/virtual reality
- 16. interactive multimedia, including audio/video conferencing
- 17. role play exercises
- 18. critical incident analysis
- 19. case studies
- 20. online mediated/tutor monitored discussion groups

CURRICULUM THEMES AND LEARNING OBJECTIVES

Each of the curriculum documents has been developed using a common format, thereby ensuring a degree of consistency and approach across the spectrum of training.

Domains

The domains are the broad fields which group common or related areas of learning.

Themes

The themes identify and link more specific aspects of learning into logical or related groups.

Learning Objectives

The learning objectives outline the specific requirements of learning. They provide a focus for identifying and detailing the required knowledge, skills, and attitudes. They also provide a context for specifying assessment standards and criteria as well as providing a context for identifying a range of teaching and learning strategies.

DOMAIN 1	FOUNDATIONS OF CLINICAL IMMUNOLOGY AND ALLERGY			
Theme 1.1	Fundamental Immunology			
Learning Objectives				
1.1.1	Explain the organisation and mechanisms of the immune system			
1.1.2	Describe the immunological mechanisms of disease			
1.1.3	Describe the pathophysiology of autoimmune and autoinflammatory diseases			
1.1.4	Describe the pathophysiology and genetics of immunodeficiency diseases			
1.1.5	Describe the pathophysiology and cell biology of allergic disease			
DOMAIN 2	INVESTIGATIONS AND MANAGEMENT			
Theme 2.1	Investigations and Therapy			
Learning Objec	tives			
2.1.1	Diagnose and manage immunodeficiency disorders and autoimmune and allergic diseases			
2.1.2	Interpret common immunopathology tests			
2.1.3	Explain the principles of immune-based therapeutics			
2.1.4	Explain the pharmacological and therapeutic management of patients with immune, inflammatory and allergic disease, including immunosuppressive therapy and the use of biologic agents			
2.1.5	Prescribe immunoglobulin and manage patients undergoing this therapy			
2.1.6	Prescribe and manage vaccines and active and passive immunisation			
2.1.7	Describe the assessment of potential donor-recipient pairs of solid organ or bone marrow transplants (BMT)			
DOMAIN 3	DISEASES AND DISORDERS			
Theme 3.1	Immunodeficiency			
Learning Objectives				
3.1.1	Assess and manage primary immunodeficiency diseases (PIDs), including inherited disorders of immune regulation			
3.1.2	Describe the assessment and management of acquired immunodeficiency			
3.1.3	Describe the assessment and management of HIV infection			

Theme 3.2	Autoimmune and Autoinflammatory disease			
Learning Objectives				
3.2.1	Assess and manage autoimmune systemic diseases			
3.2.2	Assess and manage vasculitis			
3.2.3	Assess and manage systemic autoinflammatory diseases and related disorders			
3.2.4	Diagnose and manage organ-specific autoimmune and inflammatory disease as part of a clinical team			
Theme 3.3	Allergy			
Learning Objec	tives			
3.3.1	Assess and manage rhinitis and related conditions			
3.3.2	Assess and manage allergic conjunctivitis and related conditions			
3.3.3	Assess and manage asthma and related conditions			
3.3.4	Assess and manage atopic eczema/dermatitis and related conditions			
3.3.5	Assess and manage urticaria and related conditions			
3.3.6	Assess, manage, and prevent anaphylaxis			
3.3.7	Assess, manage, and prevent adverse reactions to drugs, latex, and immunisations			
3.3.8	Assess, manage, and prevent adverse reactions to foods			
3.3.9	Explain the principles of primary prevention			
3.3.10	Assess, manage, and prevent adverse reactions to stinging or biting insects			
3.3.11	Assess and manage systemic mast cell disorders			
Theme 3.4	Clonal Disorders			
Learning Objec	tives			
3.4.1	Assess and manage systemic disorders as part of a multidisciplinary team			

DOMAIN 1		FOUNDATIONS OF CLINICAL IMMUNOLOGY AND ALLERGY				
Theme 1.1		Fundamental Immunology				
Le	arning Objective 1.1.1	Explain the organisation and mechanisms of the immune system				
Kr	nowledge					
Ev	olution and development:					
•	selective pressure on immune sy	stem during evolution				
•	principles of immune organ dev	elopment (progenitor cells and molecular regulators)				
Sti	ructure and organisation of t	he immune system:				
•	location, structure, and basic de	velopment of primary and secondary lymphoid organs.				
•	thymus, bone marrow, lymph ne mucosa-associated lymphoid tis	odes (LNs), spleen (white pulp), Peyer's patches, colonic patches, sue (MALT), including tonsils etc				
•	organisation of secondary lympl traffic in LNs	noid organs – primary and secondary follicles, T zones, principles of lymphocyte				
•	lymphocyte circulation in the bo	dy – anatomy and signals, including cellular adhesion and chemokines				
Ce	llular components of the imn	nune system:				
•	cells with recombinant receptors	s for antigen:				
	 ontogeny and distribution of T- and B-cells antigenic markers of cell subsets at different stages of ontogeny 					
•	cells with germline receptors for antigen - phagocytes, atypical lymphocytes, and dendritic cells					
An	tigen receptors – signal one:					
•	molecular mechanisms of V(D)J	recombination				
•	molecular mechanisms of somat	ic hypermutation				
•	class switch recombination					
•	toll-like receptors, dectins, and l	eucine rich repeats				
•	antigen-presentation to T-cells – antigen processing and presentation and human leukocyte antigen (HLA) molecules					
Ac	cessory signals – signal two:					
•	B7 family					
•	tumour necrosis factor receptor (TNFR) superfamily					
•	cytokine receptor families					
•	adhesion molecules					
•	complement					
Ce	ll signalling:					
•	proximal signalling after T-cell re	eceptor or B-cell receptor ligation – smac organisation and constituents				

DOMAIN 1	FOUNDATIONS OF CLINICAL IMMUNOLOGY AND ALLERGY
Theme 1.1	Fundamental Immunology
Learning Objective 1.1.1	Explain the organisation and mechanisms of the immune system
Knowledge	

Cell signalling:

- Toll like receptors signalling via myeloid differentiation primary response gene 88 (MyD88) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-kB)
- principles of cytokine signalling via janus kinase (JAK) and signal transducers and activators of transcription (STATs)

DOMAIN 1	FOUNDATIONS OF CLINICAL IMMUNOLOGY AND ALLERGY	
Theme 1.1	Fundamental Immunology	
Learning Objective 1.1.1	Explain the organisation and mechanisms of the immune system	

Tolerance:

- central tolerance in the thymus and bone marrow clonal deletion, anergy, and receptor editing
- two-signal models of peripheral tolerance
- dominant tolerance by regulatory T-cells FoxP3+ T-cells and other regulatory T-cells

Immunological memory:

- B-cell differentiation in germinal centres, including affinity maturation
- memory B-cells (phenotype and location)
- plasma cells long-lived and short-lived
- T-cell memory subsets Th1, Th2, Th17, Tfh

Effector mechanisms:

- cytotoxicity
- antibody function
- complement
- polymorphonuclear cell recruitment and action
- mast cell mediators
- acute phase response
- fibrosis.

Teaching and Learning Methods

1, 2, 5, 6, 7, 8, 14, 16, 20

DOMAIN 1	FOUNDATIONS OF CLINICAL IMMUNOLOGY AND ALLERGY				
Theme 1.1	Fundamental Immunology				
Learning Objective 1.1.2	Describe the immunological mechanisms of disease				
Knowledge					
• explain the immunological med	hanisms of disease including:				
Hypersensitivity responses – Ty	pe I:				
• cells of the allergic reaction – m	ast cells, basophils, and eosinophils				
• generation and regulation of Th	2 responses				
• cytokines/chemokines relevant	n allergic responses				
• immunoglobulin E (IgE) and rec	eptor interactions				
• IgE-mediated acute-phase and I	ate-phase reactions				
Biology of Allergens:					
• allergens					
Hypersensitivity responses – typ	bes II – IV:				
• antibody-mediated cytotoxicity	responses				
immune complexes – immunologic properties and mechanisms of clearance					
• cell mediated immunity; types l	cell mediated immunity; types IV a,b,c,d				
Transplantation immunology:					
allograft rejection					
• graft vs. host reactions					
• maintenance of tolerance					
Tumour immunology:					
• tumour specific and tumour ass	ociated antigens				
• oncogenes, translocations and t	umour suppressor genes				
• immune surveillance	immune surveillance				
Immune response to infections:					
intestinal parasites					
extracellular bacteria					
• viruses	viruses				
• intracellular bacteria – mycobac	intracellular bacteria – mycobacteria				
protozoa					

DOMAIN 1	FOUNDATIONS OF CLINICAL IMMUNOLOGY AND ALLERGY	
Theme 1.1	Fundamental Immunology	
Learning Objective 1.1.2	Describe the immunological mechanisms of disease	

Biology of HIV:

- HIV life cycle entry, latency and mechanisms of replication
- describe the differences between HIV-1 subtypes M, O and N, and HIV-2, and the resulting implications on diagnostic and monitoring testing strategies
- pathogenesis of HIV-induced immunodeficiency.

Teaching and Learning Methods

1, 2, 5, 6, 7, 8, 14, 16, 20

DOMAIN 1	FOUNDATIONS OF CLINICAL IMMUNOLOGY AND ALLERGY	
Theme 1.1	Fundamental Imn	nunology
Learning Objective 1.1.3	Describe the pathophysiology of autoimmune and autoinflammatory diseases	
Diseases and Disorders		Knowledge
 autoimmune systemic disorders vasculitis systemic autoinflammatory and organ specific autoimmune dise clinical team immune mediated reno-pulmor 	related disorders ase as part of a	 describe the following for common autoimmune diseases: pathophysiology, including the cell biology and molecular basis of autoimmune diseases pathogenic mechanisms underlying autoimmune diseases and features clinical presentations and features natural history genetic contributors environmental contributors epidemiology.
Teaching and Learning Methods		
1, 2, 5, 6, 7, 8, 14, 16, 20		

DOMAIN 1	FOUNDATION ALLERGY	IS OF CLINICAL IMMUNOLOGY AND	
Theme 1.1	Fundamental Immunology		
Learning Objective 1.1.4	Describe the path diseases	athophysiology and genetics of immunodeficiency	
Diseases and Disorders		Knowledge	
 the major PID as in the Internation Immunological Societies (IUIS)* combined T- and B-cell deficience predominant antibody deficienci other well defined immunodefici disorders of immune regulation: defects of programmed cell e.g. autoimmune lymphopro syndrome (ALPS) defects of cytotoxicity, e.g. H syndromes defects of regulatory T-cell si e.g. deficiency of Foxp3 congenital defects of phagor function or both defects of innate immunity autoinflammatory disorders complement deficiencies Acquired immunodeficiency including those related to: infections, including HIV infe- protein-losing conditions nutrition and metabolic diso immunosuppression, malign therapies. 	ies es encies death, bliferative naemophagocytic ignalling, cyte number, disorders , ection and others	 describe the following for common immunodeficiency diseases: pathophysiology, including the molecular basis and cell biology pathogenic mechanisms underlying immunodeficiency disease states clinical presentations and features natural history genetic contributors environmental contributors. 	
Teaching and Learning Metho	ods		
1, 2, 5, 6, 7, 8, 14, 16, 20			
*Correct as of 2007. For full article deta	ails please refer to the	reference list.	

DOMAIN 1	FOUNDATION ALLERGY	S OF CLINICAL IMMUNOLOGY AND
Theme 1.1	Fundamental Imn	nunology
Learning Objective 1.1.5	Describe the path	ophysiology and cell biology of allergic disease
Diseases and Disorders		Knowledge
Upper airway diseases:•rhinitis•sinusitis•allergic fungal sinusitis•nasal polyposis•otitis – bacterial and serousLower respiratory tract diseases•wheezing disorders of early child•exercise-induced asthma•allergic asthma•bronchopulmonary aspergillosis•sulfite-related asthma•aspirin-induced asthma•occupational asthma•infection-related asthma•intrinsic asthma•atlergic conjunctivitis•atlopic and vernal keratoconjuncDermatological diseases which I have an immunological basis:•urticaria•angioedema•dermatographism•atopic eczema/dermatitis•urticaria pigmentosa•bullous diseases	dhood	 describe the following for common allergic diseases: pathophysiology, including the molecular basis and cell biology clinical presentations and features natural history genetic contributors environmental contributors epidemiology describe normal physiology of the upper and lower airways, skin and gastrointestinal (GI) tract describe the biology of allergens and antigens explain the pathological effects of allergic and other immunologic diseases on airway physiology explain the pathogenic mechanisms underlying allergic diseases recognise the cellular phenotypes of asthma describe the role of genetics in immunological adverse drug reactions.

DOMAIN 1	FOUNDATION ALLERGY	S OF CLINICAL IMMUNOLOGY AND
Theme 1.1	Fundamental Imm	nunology
Learning Objective 1.1.5 Describe the path		ophysiology and cell biology of allergic disease
Dermatological diseases which have or may have an immunological basis:		
drug rashes		
 erythema multiforme and toxic epidermal necrolysis 		
erythema nodosum		
• other immunologic skin diseases	5.	
Anaphylaxis		
Drug reactions.		
Teaching and Learning Methods		
1, 2, 5, 6, 7, 8, 11, 13, 16, 19		

DOMAIN 2	INVESTIGATIC	ONS AND MANAGEMENT
Theme 2.1	Investigations and Therapy	
Learning Objective 2.1.1	Diagnose and ma and allergic diseas	nage immunodeficiency disorders and autoimmune ses
Knowledge		Skills
 describe indications, limitations, costs, and availability of tests 		 diagnose (including differential diagnosis), treat and monitor allergic diseases
 availability of tests describe the principles of investigations, including: in vitro tests for slgE and slgG use of total lgE tests of airway inflammation rhinoscopy and bronchoscopy tests for physical urticaria skin and in vitro testing for autoantibodies provocation testing of both upper and lower airways imaging describe the use of immunisation as tests of immune competence select and monitor immune based therapies to treat immunological disorders. 		 identify unproven or inappropriate methods of allergy testing used in the community diagnose (including differential diagnosis), treat and monitor immunodeficiency disorders and autoimmune diseases perform the following investigations: skin prick and intradermal testing spirometry skin patch testing elimination diets and food challenges uncomplicated skin biopsy.

DOMAIN 2	INVESTIGATIO	ONS AND MANAGEMENT
Theme 2.1	Investigations and	d Therapy
Learning Objective 2.1.2	Interpret commo	n immunopathology tests*
Knowledge		Skills
 outline the variety of immunopal including their strengths, limitatic contraindications, and complicated describe the techniques used and interpretation advise on the use of common importents with the following susporting with the following susporting and organ specific, e.g. autor disease, autoimmune, and a diseases systemic vasculitis patients with possible allerg including angioedema describe the anticipated respolysaccharide and protein healthy individuals, and how that in individuals with funct deficiencies describe the status of in vitra allergy describe the role of genetic immunologically mediated or coeliac disease and abacavir 	ons, indications, ions d their clinical munopathology nonitoring of ected or known ag: nunodeficiency s erythematosus bimmune liver utoinflammatory ic symptoms, bonses to immunisations in v this contrasts to tional antibody o tests for drug	 assess when an immunopathology test is required observe and interpret the results of the following: lymphocyte subset enumeration lymphocyte and neutrophil, functional assays, including cytokine release assays measurement of serum immunoglobulins (IgG/A/M) and IgG subclasses immunochemical complement assays C3/C4/ C1 esterase inhibitor, C1q functional complement assays, including CH50 AH50, assays for mannose-binding lectin (MBL) pathway and functional C1 inhibitor serum, urine and cerebral spinal fluid protein electrophoresis and immunofixation, including quantitation of serum light chains antineuclear antibodies (ANA), anti-extractable nuclear antigens (ENA) and anti-double stranded DNA (dsDNA) anti-neutrophil cytoplasmic antibody (ANCA), including indirect immunofluorescence and enzyme linked immunosorbent assay (ELISA) antiphospholipid related antibodies, including lupus anticoagulant, anticardiolipin, and anti-beta2-glycoprotein 'organ specific' auto-antibodies, including antibodies to smooth muscle, mitochondria, gastric parietal cell, intrinsic factor, thyroid microsomes, thyroid receptor, adrenal gland, ovary, glomerular basement membrane, islet cell, glutamic acid decarboxylase and insulin, skin rheumatoid factor and cyclic citrullinated peptide (CCP) antibodies total SIgE and in-vitro allergen-specific IgE radioallergosorbent testing, including use of recombinant allergens mast cell tryptase use immunisation with pneumococcal polysaccharide vaccine and protein vaccines, e.g. tetanus, diphtheria toxoids, to assess immune competence in patients with immunodeficiency.

DOMAIN 2	INVESTIGATIONS AND MANAGEMENT	
Theme 2.1	Investigations and Therapy	
Learning Objective 2.1.2	Interpret common immunopathology tests*	
Teaching and Learning Methods		
1-14, 16, 19, 20		
* NID This water is for the income of the line EDACD to initial this to income the later for the income of the line		

* NB: This section is for trainees undertaking FRACP training. Joint trainees should refer to the immunopathology curriculum (www.rcpa.edu.au)

DOMAIN 2	INVESTIGATIONS AND MANAGEMENT	
Theme 2.1	Investigations and Therapy	
Learning Objective 2.1.3	Explain the principles of immune-based therapeutics	
Knowledge		
• describe the pharmacology and mechanisms of action of immune-based therapies, including the following:		

- immunosuppressive and immunomodulatory drugs, including:
 - steroids
 - azathioprine
 - cyclophosphamide
 - mycophenolate
 - calcineurin inhibitors
 - methotrexate
 - leflunomide
- intravenous (IV) and subcutaneous immunoglobulin in replacement and immunomodulatory use
- therapeutic monoclonal antibodies, cytokines, soluble receptors and other biological agents used for modulation of immune and inflammatory responses, e.g. tumour necrosis factor-alpha/interlunkin-1 antagonists, anti-CD20 monoclonal antibodies, etc
- plasmapheresis
- allergen specific immunotherapy
- immunisation as prophylaxis against infectious and/or neoplastic disease
- describe the difference between T-cell dependent and independent responses to antigen and impact on disease spectrum, including age related issues.

Teaching and Learning Methods

1, 2, 5, 6, 7, 8, 11, 13, 16, 19

DOMAIN 2	INVESTIGATIO	ONS AND MANAGEMENT
Theme 2.1	Investigations an	d Therapy
Learning Objective 2.1.4	Explain the pharmacological and therapeutic management of patients with immune, inflammatory and allergic disease, including immunosuppressive therapy and the use of biologic agents	
Knowledge		Skills
 describe the following for the the below: mechanisms of action indications, including emerand contraindications pharmacology therapeutic rationale allergen preparations, e.g. allergens; the role of adjuvathe immune response routes of administration; m potential risks, adverse effector minimising. Therapies: allergen-specific immunotheraption diseases; indications, contraindio of immunisation, risks, allergen design of immunotheraption design of adverse reaction points and management of ana immunosuppressive and immure therapeutic monoclonal antiboos cytokines recombinant protein based thera soluble receptors plasmapheresis 	ging indications recombinant ants in modifying ethods of delivery cts, and methods y for allergic cations, routes selection, nes, precautions, ns and stopping phylaxis nomodulatory drugs dies	 prescribe allergen specific immunotherapy when indicated prescribe immunomodulatory therapies and plasmapheresis in autoimmune, inflammatory and PID conditions as indicated prescribe individualised management plans for autoimmune and other inflammatory diseases using including corticosteroids and immunomodulatory drugs prevent predictable adverse events of immunosuppressive therapy, including opportunistic infections and glucocorticoid induced osteoporosis monitor, detect, report, and manage response and adverse events of therapy manage IV access, including potential complications associated with intravascular access devices counsel patients and families on the potential benefits, risks, and safety plans of therapies explain the availability, cost of access, potential benefits vs. risks of gene therapy for immune deficiency disorders.
 immunoglobulin replacement and immunomodulatory therapy – refer to Learning Objective 2.1.5. 		

DOMAIN 2	INVESTIGATIC	INS AND MANAGEMENT
Theme 2.1	Investigations and	l Therapy
Learning Objective 2.1.5	Prescribe immunc therapy	oglobulin and manage patients undergoing this
Knowledge		Skills
 describe the indications for IV immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) replacement therapy for PID and systemic inflammatory disease (SID) 		 prescribe and arrange supply of IVIG according to current guidelines and limitations of issuing authorities – currently Australian Red Cross blood transfusion service
 describe the indications for IV immunoglobulin (IVIG) therapy for immunomodulation 		 advise regarding timing of prophylactic immunisations relative to immunomodulatory therapies such as IVIG
 describe the collection and manufacturing process for immunoglobulin preparations and impact on efficacy and safety 		 discuss expectations of disease reversal or control with patients and their family
 describe the major components of IVIG and describe alternative preparations of immunoglobulin 		 monitor efficacy of immunoglobulin infusions by clinical parameters, such as infections through symptoms and IgG levels.
• explain IVIG's potential adverse effects		
• describe the practicalities of pres administration and monitoring l including compliance with form	VIG therapy,	

DOMAIN 2	INVESTIGATIO	ONS AND MANAGEMENT
Theme 2.1	Investigations and	d Therapy
_earning Objective 2.1.6 Prescribe and ma		nage vaccines and active and passive immunisation
Knowledge		Skills
 describe the innate and adaptive responses to immunisations used practice, including: live attenuated and non-live against infectious diseases therapeutic immunisations a disorders therapeutic immunisations a disorders describe the basis of protein con T-cell independent antigens to m responsiveness describe the indications for immunifications diseases in high risk interployees of health care facilities high prevalence countries describe the infectious diseases t immunisations available and their reactions explain the principles, indication contraindications, risks and benerimmunisation against infectious in normal patients and those wit secondary immunosuppression contained and opinion describe the use of specific immunisation against infectious against infectious	l in clinical immunisations against allergic against malignant jugation to hodify vaccine unisations to dividuals, e.g. s and travellers to immunisation hat pose a risk, the r potential adverse s, fits of agents and cancer h primary or or asplenia on using evidence unoglobulin ectious disease	 prescribe and prepare appropriate allergen specific vaccines prescribe when indicated appropriate 'catch up' vaccine schedules advise on and prescribe immunisation against infectious agents in patients with primary or secondary immunosuppression, asplenia, and an increased risk of allergic reactions to vaccines manage adverse reactions to immunisations and advise patients and their families in regards to future immunisation schedule counsel patients and families regarding the benefits/risks of immunisation discuss vaccines that are inappropriate or require to be given in special conditions according to the immunodeficiency or allergic condition.

DOMAIN 2	INVESTIGATIONS AND MANAGEMENT
Theme 2.1	Investigations and Therapy
Learning Objective 2.1.7	Describe the assessment of potential donor-recipient pairs of solid organ or bone marrow transplant (BMT)*
NOTE	The content in this learning objective table is core for joint trainees but rarely part of FRACP practice in Australia. It is expected that trainees have a basic knowledge of these areas but specific skills are necessary for those who will work in these areas
Knowledge	

• recognise the Australian Bone Marrow Donor Registry (ABMDR) and international bone marrow donor registries

• recognise the Australian national network of umbilical cord blood banks and cord blood collection centres (AUSCORD) and international cord blood registries

- describe testing modalities available for the following:
 - HLA/major histocompatibility complex (MHC) typing
 - assessment of donor anti-recipient and recipient anti-donor reactivity
 - assessment of anti-HLA antibodies for bone marrow and solid organ transplantation
- define principles of immunosuppression and the agents/protocols used to prevent the rejection of transplanted tissues, and graft-vs.-host disease.
- describe the principles and indications of immune reconstitution following BMT and stem cell transplantation for immunodeficiency diseases
- advise on the conduct of donor searches, including immediate and extended family members
- use BMT co-ordinators and national/international bone marrow and cord blood donor registries
- explain how to assess anti-HLA antibodies in potential recipients of solid organ transplants, to help determine the risk of hyperacute rejection
- describe the management of potential recipients of solid organ transplants with established significant levels of anti-HLA antibodies
- identify potential risks involved in BMT donor/recipient pairs
- identify risks of donor anti-recipient and recipient anti-donor reactivity, including the ranking of potential donors
- advise on patients undergoing solid organ transplantation to minimise the probability of graft rejection
- outline the management principles for patients undergoing acute/chronic graft rejection
- advise on patients undergoing autologous or allogeneic bone marrow transplantation, including stem cell transplantation, to minimise the probability of graft vs. host disease and graft rejection, and/or manage patients experiencing graft-vs.-host disease.

Teaching and Learning Methods

DOMAIN 3	DISEASES AND	DISORDERS
Theme 3.1	Immunodeficienc	у
Learning Objective 3.1.1		ge primary immunodeficiency diseases (PIDs), d disorders of immune regulation
Knowledge		Skills
• recognise the age and ethnicity in reference ranges	related differences	 diagnose immunodeficiency states and inherited disorders of immune regulation
• anticipate, detect, manage and prevent complications of immu		 distinguish primary from acquired immunodeficiency diseases
• describe the defects of central tolerance induction, e.g. autoimmune polyendocrinopathy-candidiasis-		• interpret the results of genetic tests for these disorders
ectodermal dystrophyoutline the Australasian PID data	tabase	 monitor and manage subjects with PID and disorders of immune regulation
 describe the support organisations available for patients with PID. 		 anticipate likely infections and neoplasias according to the PID condition
		• instruct patients and families in use of prophylactic antibiotics and replacement immunoglobulin
		• explain early detection of infections and neoplasia and provide a management plan
		 advise on appropriate and inappropriate vaccines according to the PID advise regarding benefits and risks and prescribe as indicated reconstitutive therapy
		enrol patients in the Australian PID database
		 recognise age related differences in infection susceptibility including the impact of transplacental IgG transfer and the effect of ageing on the immune system
		 distinguish between transient hypogammaglobulinaemia of infancy and primary immunodeficiency of childhood.
Teaching and Learning Met	hods	·

DOMAIN 3	DISEASES AND DISORDERS
Theme 3.1	Immunodeficiency
Learning Objective 3.1.2	Describe the assessment and management of acquired immunodeficiency
Knowledge	

avalain the likely patterns/presentation

• explain the likely patterns/presentations assessment and management of immunodeficiency when present in patients following immunosuppression, haematological malignancy anti-tumour chemotherapy, bone marrow, or solid organ transplantation.

Teaching and Learning Methods

1-14, 16, 19, 20

DOMAIN 3	DISEASES AND DISORDERS
Theme 3.1	Immunodeficiency
Learning Objective 3.1.3	Describe the assessment and management of HIV infection
ΝΟΤΕ	It is expected that trainees have a basic knowledge of this area but specific skills are necessary for those who will work in these areas

Knowledge

- describe the differences between HIV-1 subtypes M, O and N, and HIV-2
- identify the principles of diagnosing HIV infection when present in patients presenting with clinical immunodeficiency states
- describe the therapy for HIV infection, including: indications for use, pharmacology, adverse drug reactions, and the role of resistance testing
- describe testing methodologies for establishing HIV infection, including indications, limitations, costs, and availability
- recognise the process of notification for new HIV diagnoses to public health
- describe testing methodologies for the monitoring of patients infected with HIV
- outline antiretroviral therapy, including the positive and negative aspects; when to start, drug interactions, prevention of short- and long-term toxicity, causes of treatment failure
- describe factors that influence patient compliance with antiretroviral therapy
- describe the social and psychological impact of HIV infection on patients and their families/companions, including the available support options
- describe the community support organisations available to provide advice and assistance to patients with HIV infection
- explain the prevention methods of HIV transmission, including mother to child transmission of HIV
- advise and/or provide pre and post test counselling for individuals suspected of exposure to HIV infection
- describe the principles of occupational and non-occupational post-exposure prophylaxis

DOMAIN 3	DISEASES AND DISORDERS
Theme 3.1	Immunodeficiency
Learning Objective 3.1.3	Describe the assessment and management of HIV infection
ΝΟΤΕ	It is expected that trainees have a basic knowledge of this area but specific skills are necessary for those who will work in these areas

Knowledge

- recognise diagnostic tests used for HIV infection, including testing during suspected seroconversion illness, and patients suspected being infected with HIV-1 subtypes O and N, and HIV-2
- recognise the role of resistance testing and R5/X4 tropism assays
- describe how to diagnose, manage, and prevent complications of advanced HIV, including appropriate prophylaxis against opportunistic infections and early diagnosis and treatment of likely infections and neoplasias and vascular and metabolic disorders
- describe the principles of management of hepatitis B and C, and HIV co-infected patients
- outline the palliative care of late disease.

Teaching and Learning Methods

1-14, 16, 19, 20

DOMAIN 3	DISEASES AND DISORDERS
Theme 3.2	Autoimmune and Autoinflammatory Diseases
Learning Objective 3.2.1	Assess and manage autoimmune systemic diseases
Conditions include:	

- systemic lupus erythematosus, including neonatal lupus syndrome
- Sjögren's syndrome
- mixed connective tissue disease
- dermatomyositis and polymyositis
- scleroderma
- primary Raynaud's disease
- anti-phospholipid antibody syndromes primary and secondary
- undifferentiated connective tissue diseases
- IgG4 multi-organ lymphoproliferative syndrome.

Additional Conditions

NOTE: It is expected that trainees have a basic knowledge of the following area but specific skills are necessary for those who will work in those areas

Theme 3.2 Learning Objective 3.2.1 Additional Conditions NOTE: It is expected that trainees have those who will work in those areas • rheumatoid arthritis • seronegative spondyloarthropathin • ankylosing spondylitis • seronegative enthesopathy ar • Reiter's syndrome • arthritis and inflammatory bo • psoriatic arthritis • juvenile idiopathic arthritis • Sjögren's syndrome.	nd arthropathy syndrome
Learning Objective 3.2.1 Additional Conditions NOTE: It is expected that trainees have those who will work in those areas • rheumatoid arthritis • seronegative spondyloarthropathic • ankylosing spondylitis • seronegative enthesopathy ar • Reiter's syndrome • arthritis and inflammatory bo • psoriatic arthritis • juvenile idiopathic arthritis • Sjögren's syndrome. Skills • diagnose and monitor autoimmur	Assess and manage autoimmune systemic diseases the a basic knowledge of the following area but specific skills are necessary for ies: nd arthropathy syndrome
Additional Conditions NOTE: It is expected that trainees have those who will work in those areas • rheumatoid arthritis • seronegative spondyloarthropathi • ankylosing spondylitis • seronegative enthesopathy ar • Reiter's syndrome • arthritis and inflammatory bo • psoriatic arthritis • juvenile idiopathic arthritis • Sjögren's syndrome. Skills • diagnose and monitor autoimmur	re a basic knowledge of the following area but specific skills are necessary for ies: nd arthropathy syndrome
 NOTE: It is expected that trainees have those who will work in those areas rheumatoid arthritis seronegative spondyloarthropathie ankylosing spondylitis seronegative enthesopathy ar Reiter's syndrome arthritis and inflammatory bo psoriatic arthritis juvenile idiopathic arthritis Sjögren's syndrome. Skills	ies: nd arthropathy syndrome
 seronegative spondyloarthropathie ankylosing spondylitis seronegative enthesopathy ar Reiter's syndrome arthritis and inflammatory bo psoriatic arthritis juvenile idiopathic arthritis Sjögren's syndrome. Skills diagnose and monitor autoimmur 	nd arthropathy syndrome
diagnose and monitor autoimmur	Jiver disease
•	
 anti-citrullinated protein antik protein (CRP), ANCA, anti-ph sediment imaging studies relevant to p investigations of respiratory fu in patients with rheumatologi perform uncomplicated skin biops 	n to rheumatic conditions, including ANA, ENA, rheumatoid factor, bodies, lupus anticoagulant, erythrocyte sedimentation rate (ESR), C-reactive nospholipid antibodies, immunoglobulins, complement, biopsies, and urinary patients with systemic autoimmune disorders function, including lung volumes and diffusing lung capacity output (DLCO) gical disorders
• perform Schirmer's test.	
Teaching and Learning Metho	ods

DOMAIN 3	DISEASES AND DISORDERS			
Theme 3.2	Autoimmune and Autoinflammatory Diseases			
Learning Objective 3.2.2	Assess and manage vasculitis			
Conditions include:				
 small vessel vasculitis: Henoch-Schonlein purpura Wegener's granulomatosis Goodpasture's syndrome Churg-Strauss syndrome microscopic polyangiitis cryoglobulinaemia leukocytoclastic and lymph medium vessel vasculitis: polyarteritis nodosa central nervous system vasc large vessel vasculitis: Takayasu arteritis Kawasaki syndrome giant cell arteritis. 	ocytic vasculitis confined to the skin			
Skills				
imaging studies relevant totests of respiratory functionuncomplicated skin biopsie	vasculitic conditions including interpretation of: patients with systemic vasculitides n, including lung volumes and DLCO s pertain to systemic vasculitides, e.g ANA, ENA, dsDNA, ANCA, protein			
electrophoresis, cryoglobulins, r	heumatoid factor, anti-CCP, ESR, CRP, anti-phospholipid antibodies, lupus s, complement, biopsies, hepatitis and HIV serologies and urinary sediment.			

DOMAIN 3	DISEASES AND DISORDERS	
Theme 3.2	Autoimmune and Autoinflammatory Diseases	
Learning Objective 3.2.3	Assess and manage systemic autoinflammatory diseases and related disorders	

Conditions include:

- cyclical neutropenia
- familial Mediterranean fever
- tumour neucrosis alpha receptor associated peroidic syndrome (TRAPS)
- hyper-IgD
- periodic fever with aphthous stomatitis, pharyngitis, and adenitis syndrome
- Behcet's
- sarcoidosis
- chronic infantile neurological, cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome
- Muckel-Wells syndrome
- chronic recurrent multi-focal osteomyelitis.

Skills

- diagnose and monitor systemic autoinflammatory and related disorders, including interpretation of:
 - laboratory results that pertain to the listed inflammatory disorders, e.g. ESR, CRP, serum angiotensin-converting enzyme (ACE), IgD, biopsies and genetic studies
 - imaging studies relevant to patients with systemic inflammatory disorders
 - tests of respiratory function, including lung volumes and DLCO
- treat and manage patients with these disorders.

Teaching and Learning Methods

DOMAIN 3	DISEASES AND DISORDERS	
Theme 3.2	Autoimmune and Autoinflammatory Diseases	
Learning Objective 3.2.4	Diagnose and manage organ-specific autoimmune and inflammatory disease as part of a clinical team	
NOTE	It is expected that trainees have a basic knowledge of this area but specific skills are necessary for those who will work in these areas	

Conditions include:

- autoimmune cutaneous disorders, including:
 - autoimmune bullous skin disorders
 - vitiligo
 - Sweet's syndrome
 - pyoderma gangrenosum
- autoimmune neurological disorders, including:
 - myasthenia gravis and related syndromes
 - Guillain-Barré syndrome
 - chronic idiopathic demyelinating polyneuropathy
 - multiple sclerosis
 - optic neuritis
 - paraneoplastic syndromes
- inflammatory eye disorders:
 - optic neuritis
 - iritis/uveitis
 - episcleritis
 - orbital myositis
- autoimmune haematological condition, including:
 - autoimmune neutropenia
 - autoimmune thrombocytopenia
 - autoimmune haemolytic anaemia
- autoimmune endocrinolgical disorders, including:
 - thyroid disease Hashimoto's and Graves'
 - parathyroid disease autoimmune hypoparathyroidism
 - adrenal disease Addison's
 - ovarian failure
 - endocrinopathy syndromes multiple endocrine neoplasia and polyglandular
- autoimmune gastroenterological disorders, including:
 - coeliac disease
 - pernicious anaemia
 - autoimmune hepatitis
 - primary biliary cirrhosis.

DOMAIN 3	DISEASES AND DISORDERS
Theme 3.2	Autoimmune and Autoinflammatory Diseases
Learning Objective 3.2.4	Diagnose and manage organ-specific autoimmune and inflammatory disease as part of a clinical team
ΝΟΤΕ	It is expected that trainees have a basic knowledge of this area but specific skills are necessary for those who will work in these areas
Skills	

• diagnose the organ specific autoimmune condition, including:

- laboratory results that pertain to the listed syndromes
- imaging studies relevant to patients with organ-specific autoimmune diseases
- perform uncomplicated skin biopsies.

Teaching and Learning Methods

DOMAIN 3	DISEASES AND	DISORDERS
Theme 3.3 Allergy		
Learning Objective 3.3.1	Assess and manag	ge rhinitis and related conditions
Knowledge		Skills
 explain the principles of therapy and monitoring of allergic respiratory disease and related conditions describe the differential diagnoses of allergic nasal conditions identify normal sino-nasal anatomy and changes associated with allergic or eosinophillic inflammation describe inflammatory changes in chronic rhinosinusitis with and without nasal polyposis describe the technique of nasal provocation and assessment outline surgical therapies of the nasal airway. 		 perform and interpret skin testing and in vitro slgE for aeroallergens relating to respiratory allergic diseases interpret upper airway imaging studies perform or refer for rhinoscopy as appropriate prescribe management plans, including environmental avoidance measures, pharmacotherapy and where indicated, allergen specific immunotherapy use drug delivery devices.
Teaching and Learning Meth	ods	
1-14, 18, 19		

DOMAIN 3	DISEASES AND DISORDERS
Theme 3.3	Allergy
Learning Objective 3.3.2	Assess and manage allergic conjunctivitis and related conditions
Skills	

- perform skin and in vitro testing for slgE to aeroallergens
- prescribe management plans, including environmental avoidance measures, pharmacotherapy, and, where indicated allergen-specific immunotherapy.

Teaching and Learning Methods

1-14, 18, 19

DOMAIN 3	DISEASES AND	D DISORDERS
Theme 3.3	Allergy	
Learning Objective 3.3.3	Assess and manag	ge asthma and related conditions
Knowledge		Skills
 explain the principles of therapy allergic respiratory disease and r describe the differential diagnost respiratory conditions explain wheezing disorders of explain wheezing disorders of explain the mechanisms of aspir disease. 	elated conditions es of allergic lower arly childhood	 perform and interpret the following tests: skin and in vitro testing for slgE to aeroallergens in vitro testing for slgG and use of total lgE interpret airway imaging studies perform and interpret spirometry interpret sputum cytology for asthma prescribe management plans, including environmental avoidance measures, pharmacotherapy, and where indicated, allergenspecific immunotherapy assess, monitor, and manage patients, including: reliever, preventer and symptom controller therapy immunodulatory therapy drug delivery devices use of action plans aspirin challenge testing and desensitisation community and legislative aspects knowledge of support groups.
Teaching and Learning Meth	ods	

1-14, 18, 19

DOMAIN 3	DISEASES AND DISORDERS				
Theme 3.3	Allergy Assess and manage atopic eczema/dermatitis and related conditions				
Learning Objective 3.3.4					
Knowledge		Skills			
 explain the principles of diagnosis, differential diagnoses and assessment of atopic eczema and related conditions describe the indications, contraindications, potential beneficial and adverse effects of medical therapies, including: topical glucocorticoids topical and systemic calcineurin inhibitors other immunosuppressive strategies 		 identify triggers through appropriate use of the following tests: skin and in vitro testing for slgE to aeroallergens and foods perform patch tests to foods dietary elimination and challenge studies prescribe individualised management plans for patients with atopic eczema and related disorders, including: 			
			 describe immunological comort exist in patients with atopic ecz 		 environmental avoidance measures general skin care topical +/- systemic pharmacotherapy
			 identify community resources a with atopic dermatitis 	vailable to patients	where indicated, allergen specific immunotherapy
 describe the epidemiology of al childhood 	lergic disorders in	diagnose and manage any comorbidities			
 describe the risk factors for the allergic disorders. 	development of	 educate families on management and the community resources available counsel parents at high risk of having children with allergies on strategies to reduce the risk of their child/children developing allergic diseases. 			

Teaching and Learning Methods

1-14, 18, 19

DOMAIN 3	DISEASES AND	DISORDERS
Theme 3.3	Allergy	
Learning Objective 3.3.5	Assess and manag	e urticaria and related conditions
Knowledge		Skills
 describe identifiable underlying a recurrent and chronic urticaria a physical urticarias and related co describe the mode of inheritance laboratory test abnormalities, an available for hereditary angioede describe systemic conditions wh urticaria/angioedema vasculitic urticaria familial cold urticaria (vascu) systemic mast cell disorders. 	nd angioedema, nditions e, complications, d treatments ema ich may present as litis)	 perform provocative tests for physical urticarias diagnose relevant allergic triggers using history and tests for allergen-specific IgE perform skin biopsies prescribe individualised management plans for patients with urticaria and angioedema, including: avoidance of exacerbating/precipitating factors pharmacotherapy, including:

1-4, 18, 19

DOMAIN 3	DISEASES AND	D DISORDERS
Theme 3.3	Allergy	
Learning Objective 3.3.6	Assess, manage, and prevent anaphylaxis	
Knowledge		Skills
 describe the common triggers of describe the co-factors, e.g. food may exacerbate anaphylaxis describe the differential diagnost anaphylaxis describe the mediators of diagno anaphylaxis describe the drugs and dosages, replacement required to manage describe the tests available to idd co-factors involved in anaphylaxi describe the indications, contrain and precautions required to perf procedures describe the indications, contrain and benefits of immunotherapy describe the community resource prevent and manage acute anap community recognise food science, entomol metabolism as relevant to invest anaphylaxis. 	d and exercise, that es of recurrent ostic use in postural and fluid e acute anaphylaxis entify triggers and is ndications, risks, for anaphylaxis es required to hylaxis in the ogy, and drug	 manage and investigate anaphylaxis manage acute anaphylaxis interpret serum tryptase identify responsible triggering allergens, e.g. penicillin, latex, food and insect stings, and cofactors, e.g. heat and exercise, that precipitate each patient's anaphylaxis counsel patient/patient's family on avoidance strategies counsel patient/patient's family on recognition and acute management of anaphylaxis, including administration of injectable adrenaline and autoinjectors liaise with schools/workplaces use alert systems prescribe and administer allergen immunotherapy where indicated.

Theme 3.3		
	Allergy	
Learning Objective 3.3.7	Assess, manage, a immunisations	and prevent adverse reactions to drugs, latex, and
Knowledge		Skills
 describe the clinical presentation Coombs type I, II, III and IV a,b, to drugs, latex, and immunisation describe the clinical presentation history of syndromes that may r drug reactions including anaphy spectrum of rashes, phototoxicit 'serum sickness', toxic epiderma Steve-Johnson syndrome describe the risk factors for and latex allergy describe the clinical presentation history of adverse reactions to a steroidal anti-inflammatory drug describe the diverse adverse rear result from use of biological age advise on use or no-use of chem describe the testing for 'sensitivi anaphylactic/allergic reactivities agents. 	c,d hypersensitivity ons n and natural relate to adverse ylaxis, a wide ty, drug fever, al necrolysis and presentations of n and natural spirin and non- gs ctions that may ents hically related drugs ity' to potential	 diagnose type 1 adverse reactions to drugs diagnose other severe, adverse drug reactions, including use and interpretation, of skin prick, intradermal, skin patch and in vitro testing for various type IV hypersensitivities perform and manage challenge procedures when indicated using established protocols diagnose, manage, and prevent latex allergy distinguish between hypersensitivity and intolerance minimise risks of re-exposure through use of alert systems, education, and when indicated, institution of latex free environments de-label patients perform desensitisation procedures, when indicated, using established protocols.

DOMAIN 3	DISEASES AN	D DISORDERS	
Theme 3.3	Allergy		
Learning Objective 3.3.8 Assess, ma		age, and prevent adverse reactions to foods	
Knowledge		Skills	
 describe immune mediated adverse foods, including: IgE-mediated partially IgE mediated, e.g. or inflammatory GI disorders and dermatitis non-IgE mediated, e.g. types food proteins in infants, coes describe the clinical presentation history of intolerances to foods, and other substances explain the basic concepts of food applicable to food allergies and it describe the community and leg relevant to managing food allergies and it describe the preparations available delivery, indications, and potent of pharmacotherapies for eosino describe the basis of infant nutritirelated immune adaptation, incl breast feeding and hypo-allerger describe food pollen sensitivity set 	eosinophilic nd atopic e 4 reactions to diac disease a and natural additives, lactose, od science as intolerances islative matters by easures in the diseases ole, modes of ial adverse effects philic GI diseases tion and feeding uding the role of hic formulae ivity to particular yndromes.	 distinguish between hypersensitivity and intolerance perform skin and in vitro slgE testing for type I hypersensitivity and provocative perform food challenges, open, single and double blind, when appropriate, use established protocols and be able to evaluate evolving desensitisation procedures institute dietary restrictions whilst ensuring adequate nutrition, especially in infancy counsel patients on foods as hidden allergens implement plans for management of food allergy in the community, including: action plans provision of adrenalin autoinjectors when ap- propriate school and travel plans diagnose eosinophilic GI diseases on history and interpretation of results of investigations including biopsies obtained at GI endoscopy interpret results of investigations to determine allergic triggers of eosinophilic GI diseases manage patients diagnosed with eosinophilic GI diseases, including: avoidance strategies to assist in the diagnosis and management of eosinophilic GI diseases prescription of appropriate pharmacotherapy and monitoring of these interventions 	
Teaching and Learning Meth	ods		

DOMAIN 3	DISEASES AND	DISORDERS
Theme 3.3	Allergy	
Learning Objective 3.3.9	Explain the princi	ples of primary prevention
Knowledge		Skills
• describe the efficacy of interventions to reduce the risk of development of allergic disorders in children.		 counsel parents at high risk of having a child with allergies on strategies to reduce the risk of their child/children developing allergic diseases.

DOMAIN 3	DISEASES AND	DISORDERS
Theme 3.3	Allergy	
Learning Objective 3.3.10	Assess, manage, a insects	and prevent adverse reactions to stinging or biting
Knowledge		Skills
 describe the species of stinging responsible for life-threatening h reactions in humans, including l describe the spectrum of advers stinging and biting insects describe the natural history of al insects without, during and afte immunotherapy. 	nypersensitivity ocal relevance e reactions to llergy to stinging	 diagnose type 1 adverse reactions to stinging and biting insects prescribe and write anaphylaxis action plans incorporating, when appropriate, adrenaline autoinjectors teach administration of adrenaline autoinjectors prescribe and administer venom immunotherapy, where indicated; select and manage immunotherapy protocols appropriate to the clinical situation advise patients of the risks/benefits of starting, continuing, withholding, or ceasing venom immunotherapy.
Teaching and Learning Meth	ods	
1-14, 16, 19, 20		

DOMAIN 3	DISEASES AND	DISORDERS
Theme 3.3	Allergy	
Learning Objective 3.3.11	Assess and manag	ge systemic mast cell disorders
Knowledge		Skills
 describe the spectrum and prog mast cell disorders describe the common triggers of events in subjects with systemic identify the complications of systemic disorders. 	of acute activation mast cell disorders	 prescribe and monitor therapy for systemic mast cell disorders, including: symptomatic therapy when appropriate action plans incorporating adrenaline autoinjectors when appropriate, specific allergen immunotherapy, e.g. sting allergy recognise aggressive mast cell disease and refer for systemic suppressive therapy.
Teaching and Learning Methods		
1-14, 16, 19, 20		

DOMAIN 3	DISEASES AND DISORDERS
Theme 3.4	Clonal Disorders
Learning Objective 3.4.1	Assess and manage systemic disorders as part of a multidisciplinary team

Knowledge

• recognise and describe the following systemic disorders:

Plasma cells:

- disorders related to paraproteins:
 - plasmacytoma, multiple myeloma, monoclonal gammopathy of uncertain significance, scleromyxedema, light chain deposition disease, amyloidosis and neuropathy etc

B-cell disorders*

T-cell disorders*

• *especially lymphoproliferative diseases associated with autoimmune manifestations, e.g. angioimmunoblastic T-cell lymphoma

Hypereosinophilia without defined cause:

• aggressive mast cell disorders – refer 3.3.11.

Teaching and Learning Methods

REFERENCE LIST

Curriculum of the American Academy of Allergy, Asthma and Immunology

Curriculum of the Joint Committee of Higher Medical Training (UK) for Immunology

Curriculum of the Joint Committee of Higher Medical Training (UK) for Allergy

RECOMMENDED READING LIST/LEARNING RESOURCES

Basic Texts

Crowe S, Hoy J and Mills J (eds). Management of the HIV-infected patient. published by Martin Dunitz Ltd, London (last edition 2002)

Hoy J, Lewin S, Post JJ and Street A (eds). HIV Management in Australasia – a guide for clinical care. Published by ASHM. Latest edition 2009.

Free download from http://www.ashm.org.au/images/Publications/Monographs/HIV_Management_Australasia/HIV-Management-Australia-2009.pdf

Janeway CA Jr (Ed) Immunobiology. The immune system in health and disease. 6th Edition. Elsevier 2007

Kindt TJ, Goldsby RA, Osborne BA. Kuby Immunology. 6th Edn. WH Freeman and Company: New York 2007

Rabson A, Roitt IM, Delves PJ. Really essential medical immunology. 2nd Edition. Blackwell Pub: Malden, Mass. 2005

Reference Books

Adkinson NF, Busse W, Bruce S et al. Middleton's Allergy – principles and practice. 7th ed. Philadelphia: Mosby/ Elsevier; 2009.

Detrick B, Hamilton RG, Folds JD, editors. Manual of molecular and clinical laboratory immunology. 7th ed. Washington DC: ASM Press; 2006.

Geha, R, Notarangelo, L et al. The International Union of Immunological Societies (IUIS) Primary Immunodeficiency Diseases (PID) Classification Committee: J Allergy Clin Immunol. 2007 Oct; 120(4): 776–794. doi:10.1016/j. jaci.2007.08.053.

Leung DYM, Sampson HA, Geha RS, Szefler SJ, editors, Pediatric Allergy: Principles and Practice. Philadelphia: Mosby/ Elsevier; 2003.

Paul WE, editor. Fundamental Immunology. 6th ed. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2008.

Rezaei N, Aghamohammadi A (Ed), Notarangelo, L (Ed). Primary Immunodeficiency Diseases: Definition, Diagnosis, and Management. 1st ed. Springer, 2010.

Rich RR (Ed). Clinical immunology, principles and practice. 3rd ed. St Louis: Mosby/Elsevier; 2008.

Stiehm ER, editors et al. Immunologic diseases in infants and children. 5th ed:. Elsevier Saunders; 2004.

For frequently updated information on HIV refer to online resources listed below

Journals	
Good reviews in clinical immunology and allergy can be found in the following journals.	
Nature Reviews Immunology	www.nature.com.au
New England Journal of Medicine	www.nejm.org
Current Opinion in Immunology	www.elsevier.com/wps/find/journaldescription.cws_ home/601305/description?navopenmenu=-2
Trends in Immunology	www.immunology.trends.com
Journal of Allergy and Clinical Immunology	www.jacionline.org
Nature Clinical Practice Rheumatology	www.nature.com/nrrheum/index.html
Useful computer resources	
Australasian Society of Clinical Immunology and Allergy Homepage	www.allergy.org.au
American Academy of Allergy Asthma and Immunology Homepage	www.aaaai.org
ASHM publications	www.ashm.org.au/default2.asp?active_page_id=133
Australian Immunisation Handbook 9th edition	www.health.gov.au/internet/immunise/publishing.nsf/ Content/Handbook-home
Criteria for the Clinical Use of IV Immunoglobulin (IVIg) in Australia	www.nba.gov.au/ivig/index.html
RACP Homepage	www.racp.edu.au
RCPA Homepage	www.rcpa.edu.au
Australasian Society of HIV Medicine Homepage	www.ashm.org.au
AIDSinfo: U.S. Department of Health and Human Services (DHHS)	www.aidsinfo.nih.gov

ACRONYMS AN	D INITIALISMS
ABMDR	Australian Bone Marrow Donor Registry
ACE	angiotensin-converting enzyme
ALPS	autoimmune lymphoproliferative syndrome
ANA	antineuclear antibodies
ANCA	anti-neutrophil cytoplasmic antibody
AUSCORD	Australian national network of umbilical cord blood banks and cord blood collection centres
ВМТ	bone marrow transplant
ССР	cyclic citrullinated peptide
CRP	C-reactive protein
DLCO	diffusing lung capacity output
DsDNA	double stranded deoxyribonucleic acid
ELISA	enzyme linked immunosorbent assay
ENA	anti-extractable nuclear antigens
ESR	erythrocyte sedimentation rate
GI	gastrointestinal
IUIS	International Union of Immunological Societies
lgE	immunoglobulin E
IV	intravenous
IVIG	intravenous immunoglobulin
JAK	janus kinase
LN	lymph node
MALT	mucosa-associated lymphoid tissue
MBL	mannose-binding lectin
MDT	multidisciplinary team
MGUS	monoclonal gammopathy of uncertain significance
МНС	major histocompatibility complex
MyDD88	myeloid differentiation primary response gene 88
NF-kB	nuclear factor kappa-light-chain-enhancer of activated B-cells

ACRONYMS AND INITIALISMS	
PID	primary immunodeficiency disease
SCIG	subcutaneous immunoglobulin
slgE	serum immunoglobulin E
STAT	signal transducer and activator of transcription
TNFR	tumour necrosis factor receptor
TRAPS	tumour neucrosis alpha receptor associated peroidic syndrome

Clinical Immunology and Allergy Advanced Training Curriculum

